Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

320 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A third anti-SARS-CoV-2 mRNA dose does not overcome the pejorative impact of anti-CD20 therapy and/or low immunoglobulin levels in patients with lymphoma or chronic lymphocytic leukemia.
Kohn M, Delord M, Chbat M, Guemriche A, Merabet F, Roupie AL, Lombion N, Farhat H, Longval T, Cabannes-Hamy A, Lambert J, Marque-Juillet S, Raggueneau V, Osman J, Spentchian M, Rigaudeau S, Rousselot P, Besson C. Kohn M, et al. Among authors: rousselot p. Haematologica. 2022 Jun 1;107(6):1454-1459. doi: 10.3324/haematol.2021.280026. Haematologica. 2022. PMID: 34788987 Free PMC article. No abstract available.
Adverse prognostic significance of CD20 expression in adults with Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia.
Maury S, Huguet F, Leguay T, Lacombe F, Maynadié M, Girard S, de Labarthe A, Kuhlein E, Raffoux E, Thomas X, Chevallier P, Buzyn A, Delannoy A, Chalandon Y, Vernant JP, Rousselot P, Macintyre E, Ifrah N, Dombret H, Béné MC; Group for Research on Adult Acute Lymphoblastic Leukemia. Maury S, et al. Among authors: rousselot p. Haematologica. 2010 Feb;95(2):324-8. doi: 10.3324/haematol.2009.010306. Epub 2009 Sep 22. Haematologica. 2010. PMID: 19773266 Free PMC article.
Randomized study of intensified anthracycline doses for induction and recombinant interleukin-2 for maintenance in patients with acute myeloid leukemia age 50 to 70 years: results of the ALFA-9801 study.
Pautas C, Merabet F, Thomas X, Raffoux E, Gardin C, Corm S, Bourhis JH, Reman O, Turlure P, Contentin N, de Revel T, Rousselot P, Preudhomme C, Bordessoule D, Fenaux P, Terré C, Michallet M, Dombret H, Chevret S, Castaigne S. Pautas C, et al. Among authors: rousselot p. J Clin Oncol. 2010 Feb 10;28(5):808-14. doi: 10.1200/JCO.2009.23.2652. Epub 2010 Jan 4. J Clin Oncol. 2010. PMID: 20048183 Clinical Trial.
Fractionated doses of gemtuzumab ozogamicin with escalated doses of daunorubicin and cytarabine as first acute myeloid leukemia salvage in patients aged 50-70-year old: a phase 1/2 study of the acute leukemia French association.
Farhat H, Reman O, Raffoux E, Berthon C, Pautas C, Kammoun L, Chantepie S, Gardin C, Rousselot P, Chevret S, Dombret H, Castaigne S. Farhat H, et al. Among authors: rousselot p. Am J Hematol. 2012 Jan;87(1):62-5. doi: 10.1002/ajh.22201. Epub 2011 Nov 10. Am J Hematol. 2012. PMID: 22072535 Free article. Clinical Trial.
False positive galactomannan Platelia due to piperacillin-tazobactam.
Gerlinger MP, Rousselot P, Rigaudeau S, Billon C, Touratier S, Castaigne S, Eloy O. Gerlinger MP, et al. Among authors: rousselot p. Med Mal Infect. 2012 Jan;42(1):10-4. doi: 10.1016/j.medmal.2011.10.018. Epub 2011 Dec 5. Med Mal Infect. 2012. PMID: 22153703
Clinical efficacy of second generation tyrosine kinase inhibitor and 5-azacytidine combination in chronic myelogenous leukaemia in myeloid blast crisis.
Ghez D, Micol JB, Pasquier F, Auger N, Saada V, Spentchian M, Ianotto JC, Bourhis JH, Bennaceur-Griscelli A, Terré C, Castaigne S, Rigaudeau S, Rousselot P, de Botton S. Ghez D, et al. Among authors: rousselot p. Eur J Cancer. 2013 Nov;49(17):3666-70. doi: 10.1016/j.ejca.2013.07.147. Epub 2013 Aug 19. Eur J Cancer. 2013. PMID: 23968731
High imatinib dose overcomes insufficient response associated with ABCG2 haplotype in chronic myelogenous leukemia patients.
Delord M, Rousselot P, Cayuela JM, Sigaux F, Guilhot J, Preudhomme C, Guilhot F, Loiseau P, Raffoux E, Geromin D, Génin E, Calvo F, Bruzzoni-Giovanelli H. Delord M, et al. Among authors: rousselot p. Oncotarget. 2013 Oct;4(10):1582-91. doi: 10.18632/oncotarget.1050. Oncotarget. 2013. PMID: 24123600 Free PMC article. Clinical Trial.
Complex karyotype in mantle cell lymphoma is a strong prognostic factor for the time to treatment and overall survival, independent of the MCL international prognostic index.
Sarkozy C, Terré C, Jardin F, Radford I, Roche-Lestienne C, Penther D, Bastard C, Rigaudeau S, Pilorge S, Morschhauser F, Bouscary D, Delarue R, Farhat H, Rousselot P, Hermine O, Tilly H, Chevret S, Castaigne S. Sarkozy C, et al. Among authors: rousselot p. Genes Chromosomes Cancer. 2014 Jan;53(1):106-16. doi: 10.1002/gcc.22123. Epub 2013 Oct 29. Genes Chromosomes Cancer. 2014. PMID: 24249260
Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease.
Rousselot P, Charbonnier A, Cony-Makhoul P, Agape P, Nicolini FE, Varet B, Gardembas M, Etienne G, Réa D, Roy L, Escoffre-Barbe M, Guerci-Bresler A, Tulliez M, Prost S, Spentchian M, Cayuela JM, Reiffers J, Chomel JC, Turhan A, Guilhot J, Guilhot F, Mahon FX. Rousselot P, et al. J Clin Oncol. 2014 Feb 10;32(5):424-30. doi: 10.1200/JCO.2012.48.5797. Epub 2013 Dec 9. J Clin Oncol. 2014. PMID: 24323036
320 results